GLP-1s were associated with lower risk of new substance use disorder diagnoses Across alcohol, cannabis, cocaine, nicotine, opioids, and other drug categories, people who started a GLP-1 medication were less likely to receive a new substance use disorder diagnosis over the following 3 years relative to those who started the comparison diabetes medication, sodium-glucose cotransporter-2 inhibitor
Tirzepatide (Mounjaro, Zepbound), a GLP-1/GIP dual agonist, produces greater weight loss and glucose reduction than GLP-1 agonists alone, validating the multi-agonist concept
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing
Natural Body Enhancement Treatments: The business offers HD Body Sculpting and Fat Transfer as safer and more effective alternatives to traditional methods like CoolSculpting and liposuction